Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Microbiology (medical),General Medicine
Reference26 articles.
1. Abdul-Mutakabbir JC, Griffith NC, Shields RK, Tverdek FP, Escobar ZK (2021) Contemporary perspective on the treatment of Acinetobacter baumannii infections: insights from the Society of Infectious Diseases Pharmacists. Infect Dis Ther 10(4):2177–2202
2. World Health Organisation (2017) WHO publishes list of bacteria for which new antibiotics are urgently needed, accessed on Dec 12, 2021. https://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed
3. Isler B, Doi Y, Bonomo RA, Paterson DL (2018) New treatment options against carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother 63(1):e01110–e01118
4. Da Silva GJ, Domingues S (2017) Interplay between colistin resistance, virulence and fitness in Acinetobacter baumannii. Antibiotics (Basel) 6(4):28
5. Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R et al (2021) Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 21(2):226–240
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献